Clinical and echocardiographic predictors of outcomes in patients with peripartum cardiomyopathy: A single centre, six month follow-up study

被引:11
|
作者
Kiran, G. Ravi [1 ]
RajKumar, C. [2 ]
Chandrasekhar, P. [1 ]
机构
[1] Kurnool Med Coll & Hosp, Dept Cardiol, Kurnool, India
[2] KIMS Hosp, Kurnool, India
关键词
Peripartum cardiomyopathy; Bromocriptine; Fractional area change; Ejection fraction; Left atrial volume index; Inotropes; PROGNOSTIC IMPACT; UNITED-STATES; LEVOSIMENDAN; EPIDEMIOLOGY; DYSFUNCTION;
D O I
10.1016/j.ihj.2021.01.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Peripartum cardiomyopathy (PPCM) is an important cause of maternal mortality and morbidity. But, there is a paucity of prospective data on outcomes and prognostic markers in patients receiving contemporary evidence-based therapy, particularly in developing countries. Methods: This was a single centre, prospective, cohort study on 43 PPCM patients who were followed for 6 months. The primary endpoint was a composite incidence of decompensation related rehospitalization, all-cause death, and poor recovery (defined as left ventricular ejection fraction, LVEF: <45% at 6 months). Multivariate logistic regression analysis was performed to identify the independent predictors and Kaplan-Meier plots for event (re-hospitalization or death) free survival were computed at their optimal cut-offs. Results: Mean LVEF at presentation was 34.7%. Two patients died during index hospitalization but there were no deaths during follow-up and 63.4% of patients had full LV recovery after discharge. 32.5% of the study population experienced the composite endpoint with high left atrial volume index (LAVi), and low right ventricular fractional area change (RVFAC) at presentation as independent predictors. Use of Inotropic therapy during index hospitalization (with dobutamine or levosimendan) and bromocriptine therapy were not associated with better outcome. Conclusions: At the end of 6 months after PPCM diagnosis, about 61% of patients had full LV functional recovery with a mortality rate of 4.7%. RVFAC (<31.4% with 86% accuracy) and LAVi (>29.6 ml/m(2) with 72% accuracy) at presentation but not LVEF, predicts poor outcomes. Presence of both these risk factors at index hospitalization was associated with a significantly lower event free survival compared to patients without these predictors. (C) 2021 Cardiological Society of India. Published by Elsevier B.V.
引用
收藏
页码:319 / 324
页数:6
相关论文
共 50 条
  • [1] Clinical characteristics, echocardiographic findings, and six-month outcomes in Ugandan women with peripartum cardiomyopathy: prospective case-control study
    Nabbaale, J. Juliet
    Emmy, E. O.
    Annettee, A. N.
    Graham, G. C.
    Karen, K. S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 582 - 583
  • [2] Peripartum cardiomyopathy: Clinical profile of 100 patients in a single centre prospective study
    Forster, OA
    Essop, MR
    Zhanje, F
    Candy, G
    Libhaber, E
    Phooko, B
    Libhaber, C
    Sliwa, K
    CIRCULATION, 2003, 108 (17) : 663 - 663
  • [3] DILATED CARDIOMYOPATHY - AN ECHOCARDIOGRAPHIC FOLLOW-UP OF 50 PATIENTS
    HAYAKAWA, M
    INOH, T
    FUKUZAKI, H
    JAPANESE HEART JOURNAL, 1984, 25 (06): : 955 - 968
  • [4] BEHAVIORAL THERAPY FOR COCAINE ADDICTS: OUTCOMES OF A FOLLOW-UP SIX MONTH STUDY
    Sanchez-Hervas, Emilio
    Secades-Villa, Roberto
    Zacares Romaguera, Francisco
    Garcia Fernandez, Gloria
    Santonja Gomez, Francisco Jose
    Garcia-Rodriguez, Olaya
    REVISTA MEXICANA DE PSICOLOGIA, 2010, 27 (02): : 159 - 167
  • [5] Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials
    Qianqian Xin
    Qianhui Wu
    Xinhua Chen
    Bihua Han
    Kai Chu
    Yan Song
    Hui Jin
    Panpan Chen
    Wanying Lu
    Tuantuan Yang
    Minjie Li
    Yuliang Zhao
    Hongxing Pan
    Hongjie Yu
    Lin Wang
    Nature Communications, 13
  • [6] Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials
    Xin, Qianqian
    Wu, Qianhui
    Chen, Xinhua
    Han, Bihua
    Chu, Kai
    Song, Yan
    Jin, Hui
    Chen, Panpan
    Lu, Wanying
    Yang, Tuantuan
    Li, Minjie
    Zhao, Yuliang
    Pan, Hongxing
    Yu, Hongjie
    Wang, Lin
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [7] Clinical and Echocardiographic Predictors of Clinical Outcomes in Patients with Apical Hypertrophic Cardiomyopathy
    Moon, Jeonggeun
    Shim, Chi Young
    Ha, Jong-Won
    Cho, In Jeong
    Yang, Woo-In
    Jang, Yangsoo
    Chung, Namsik
    Cho, Seung-Yun
    CIRCULATION, 2010, 122 (21)
  • [8] PROGNOSIS IN HYPERTROPHIC CARDIOMYOPATHY - ECHOCARDIOGRAPHIC FOLLOW-UP AND HISTOPATHOLOGICAL STUDY
    EMOTO, R
    YOKOTA, Y
    FUKUZAKI, H
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1989, 53 (09): : 1031 - 1044
  • [9] Clinical and Echocardiographic Predictors of Outcomes in Patients With Apical Hypertrophic Cardiomyopathy
    Moon, Jeonggeun
    Shim, Chi Young
    Ha, Jong-Won
    Cho, In Jeong
    Kang, Min Kyung
    Yang, Woo-In
    Jang, Yangsoo
    Chung, Namsik
    Cho, Seung-Yun
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (11): : 1614 - 1619
  • [10] Clinical outcomes and functional recovery after temporomandibular joint replacement: a six-month follow-up study
    Sapin-de Brosses, E.
    Bonnet, A. -S
    Zwetyenga, N.
    COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING, 2020, 23 : S270 - S272